Overview
Curai Health provides AI-assisted telemedicine for non-emergency medical needs through a digital platform that offers virtual consultations with AI chatbots and human doctors. Patients subscribe monthly or annually to access medical advice, diagnosis, and treatment plans without in-person visits. It differentiates itself through a subscription model and partnerships with employers and insurers to broaden access for remote or mobility-challenged patients. The goal is to make affordable, accessible medical care by enabling scalable, AI-enabled virtual consultations.
Work here?Claim your company
Simplify's Take
What believers are saying
- Walmart made Curai free through July 2026, proving enterprise demand and visibility.
- Rightway’s November 2024 partnership reached 1 million-plus covered members quickly.
- Curai’s 2025 SDK supports faster embedded deployments inside employer and payer apps.
What critics are saying
- Walmart’s August 2026 pricing drops Curai to $29 monthly, pressuring margins immediately.
- Curai’s public funding trail ends at 2020, signaling dependence on partner distribution.
- Incumbents like Wheel and Teladoc can bundle richer care, eroding Curai’s category.
What makes Curai unique
- Curai’s chat-first primary care integrates clinicians and AI into a single workflow.
- Rightway access and Walmart distribution extend Curai beyond standalone consumer acquisition.
- Rula referral integration gives Curai a broader care network across all states.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Industry standards
Ind Avg. $35M
$4M
$27.5M
$30M
$45M
$65M
$100M